Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 2:03 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 27,833 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo and sham treatment Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)

NCT01292473
View directory record Official record
Conditions
Chronic Idiopathic Urticaria
Interventions
Placebo, Omalizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
36
States / cities
La Jolla, California • Los Angeles, California • Redwood City, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2013 · Synced Nov 3, 2026, 2:03 PM EST
Completed Not applicable Interventional

Feasibility Study: Safety and Efficacy of the Ulthera® System for Treatment of Axillary Hyperhidrosis

NCT01713673
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Ulthera System Treatment, Sham treatment
Drug
Lead sponsor
Ulthera, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Nov 3, 2026, 2:03 PM EST
Recruiting Phase 2 Interventional

A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligo

NCT07667569
View directory record Official record
Conditions
Non-Segmental Vitiligo
Interventions
ACT-777991, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 3, 2026, 2:03 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Alpha Lipoic Acid and Insulin Resistance

NCT00845156
View directory record Official record
Conditions
Insulin Resistance
Interventions
Alpha Lipoic Acid
Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
20 Years to 60 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 2 Interventional Results available

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx

NCT04083222
View directory record Official record
Conditions
Hypertension
Interventions
Placebo, ISIS 757456
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Tustin, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Nov 3, 2026, 2:03 PM EST
Recruiting Phase 3 Interventional

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

NCT07201922
View directory record Official record
Conditions
Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
Interventions
Nerandomilast, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
13
States / cities
Los Angeles, California • Aurora, Colorado • Kissimmee, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 2 Interventional

Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Patients Receiving Chemoradiation Therapy for Head and Neck Cancer

NCT00756951
View directory record Official record
Conditions
Oral Mucositis, Head and Neck Cancer
Interventions
Placebo, SCV-07
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2009 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of LY3154207 in Healthy Participants

NCT03942029
View directory record Official record
Conditions
Healthy
Interventions
LY3154207 Capsule, LY3154207 Tablet, Placebo, Fluconazole Tablet
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Nov 3, 2026, 2:03 PM EST
Recruiting Phase 2 Interventional

HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes

NCT07546929
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
HP-211, Placebo
Drug
Lead sponsor
Housey Healthcare ULC
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
25
States / cities
Canoga Park, California • Doral, Florida • Edgewater, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 1 Interventional

Pilot Study of Bumetanide for Newborn Seizures

NCT00830531
View directory record Official record
Conditions
Seizures
Interventions
Bumetanide, Normal Saline as Placebo
Drug
Lead sponsor
Soul, Janet , M.D.
Individual
Eligibility
Up to 44 Weeks
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers

Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder

NCT03817931
View directory record Official record
Conditions
Overactive Bladder, Dementia, Lower Urinary Tract Symptoms, Incontinence, Urge
Interventions
Anticholinergic, Beta-3 Agonists, Adrenergic, Functional magnetic resonance imaging (fMRI), Rey Auditory Verbal Learning Test (RAVLT)
Drug · Diagnostic Test
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Houston, Texas • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis

NCT00488631
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Placebo, Golimumab 50 mg, Golimumab 100 mg, Golimumab 200 mg
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
96
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 93 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2016 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 2 Interventional

Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF

NCT06331624
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, IPF
Interventions
Tazarotene (GRI-0621), Placebo
Drug
Lead sponsor
GRI Bio Operations, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Newport Beach, California • Jacksonville, Florida • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 3 Interventional

Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma

NCT00044824
View directory record Official record
Conditions
Asthma
Interventions
Fexofenadine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Nov 3, 2026, 2:03 PM EST
Terminated Phase 3 Interventional Results available

Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC

NCT02954159
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Tacrolimus, Vedolizumab, Placebo
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Nov 3, 2026, 2:03 PM EST
Completed Not applicable Interventional Results available

Intense Pulsed Light Study for Dry Eye Disease

NCT03089580
View directory record Official record
Conditions
Dry Eyes Chronic
Interventions
Intense Pulsed Light Therapy, Sham Treatment
Device · Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Nov 3, 2026, 2:03 PM EST
Not yet recruiting Phase 1Phase 2 Interventional

Neuromodulation in Patients With Pulmonary Arterial Hypertension

NCT06802380
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Low-level tragus stimulation, Sham stimulation
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Nov 3, 2026, 2:03 PM EST
Recruiting Phase 2 Interventional

Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

NCT07005180
View directory record Official record
Conditions
Parkinson Disease
Interventions
HBI-002, Vehicle (placebo)
Drug
Lead sponsor
Hillhurst Biopharmaceuticals, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Fountain Valley, California • Gainesville, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 3 Interventional Results available

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

NCT00528879
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo, Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
915 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
28
States / cities
Tempe, Arizona • Encino, California • Fresno, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria

NCT03392896
View directory record Official record
Conditions
Primary Hyperoxaluria
Interventions
DCR-PHXC, Placebo
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
6 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 2 Interventional Results available

Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2

NCT02278562
View directory record Official record
Conditions
ESRD
Interventions
anakinra, actos, placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 2 Interventional Results available

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

NCT02108262
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
CSL112, Placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
1,267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
48
States / cities
Birmingham, Alabama • Huntsville, Alabama • Concord, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Nov 3, 2026, 2:03 PM EST
Completed Not applicable Interventional

A Randomized Crossover Trial of Bright Light Therapy in Irritable Bowel Syndrome

NCT06676488
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS), Circadian Misalignment
Interventions
Re-Timer glasses, Placebo Device
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 2 Interventional

A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

NCT00929188
View directory record Official record
Conditions
Pain, Burning, Pain, Crushing, Pain, Migratory, Pain, Radiating, Pain, Splitting
Interventions
JNJ-42160443, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
17
States / cities
Birmingham, Alabama • Tucson, Arizona • Laguna Hills, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Nov 3, 2026, 2:03 PM EST